ABERA Stock Overview

A platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. More details

ABERA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 21.3% per year over past 5 years

Does not have a meaningful market cap (SEK67M)

Volatile share price over the past 3 months compared to the Swedish market

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Abera Bioscience AB Competitors

Elicera Therapeutics

OM:ELIC

SEK 88.8m

Vivesto

OM:VIVE

SEK 132.9m

Dextech Medical

NGM:DEX

SEK 73.9m

Lipigon Pharmaceuticals

OM:LPGO

SEK 21.5m

Price History & Performance

Summary of share price highs, lows and changes for Abera Bioscience
Historical stock prices
Current Share Price	SEK 4.00
52 Week High	SEK 7.50
52 Week Low	SEK 3.51
Beta	1.0
1 Month Change	-12.85%
3 Month Change	1.52%
1 Year Change	-11.11%
3 Year Change	-70.91%
5 Year Change	n/a
Change since IPO	-63.80%

Recent updates

We're Not Very Worried About Abera Bioscience's (NGM:ABERA) Cash Burn Rate

Nov 03

We Think Abera Bioscience (NGM:ABERA) Can Afford To Drive Business Growth

Jul 21

Shareholder Returns

	ABERA	SE Biotechs	SE Market
7D	1.0%	2.4%	2.8%
1Y	-11.1%	13.0%	13.1%

Return vs Industry: ABERA underperformed the Swedish Biotechs industry which returned 14.4% over the past year.

Return vs Market: ABERA underperformed the Swedish Market which returned 13.7% over the past year.

Price Volatility

Is ABERA's price volatile compared to industry and market?
ABERA volatility
ABERA Average Weekly Movement	11.6%
Biotechs Industry Average Movement	9.5%
Market Average Movement	5.9%
10% most volatile stocks in SE Market	11.8%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: ABERA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: ABERA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2012	6	Maria Alriksson	aberabio.com

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.

Abera Bioscience AB Fundamentals Summary

How do Abera Bioscience's earnings and revenue compare to its market cap?
ABERA fundamental statistics
Market cap	SEK 67.09m
Earnings (TTM)	-SEK 3.72m
Revenue (TTM)	SEK 12.60m

4.9x

P/S Ratio

-16.5x

P/E Ratio

Is ABERA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABERA income statement (TTM)
Revenue	SEK 12.60m
Cost of Revenue	SEK 0
Gross Profit	SEK 12.60m
Other Expenses	SEK 16.32m
Earnings	-SEK 3.72m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 13, 2025

Earnings per share (EPS)	-0.24
Gross Margin	100.00%
Net Profit Margin	-29.50%
Debt/Equity Ratio	0%

How did ABERA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/22 12:49
End of Day Share Price	2025/01/22 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abera Bioscience AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Niklas Elmhammer	Carlsquare AB
Herman Kuntscher	Carlsquare AB